16019-31-1

Usage

Chemical Properties

Pale yellow paint, liquid

InChI:InChI=1/C7H6Cl2N2/c1-2-3-5-6(8)10-4-11-7(5)9/h2,4H,1,3H2

Upstream product

• 16019-30-0 5-(prop-2-en-1-yl)pyrimidine-4,6-diol 
• 1193-21-1 4,6-dichloropyrimidine 
• 106-95-6 allyl bromide 
• 1426659-18-8 5-(4,6-dichloropyrimidinyl)zinc pivalate 
• 40637-56-7 dimethyl allylmalonate 
• 16019-30-0 5-allyl-6-hydroxy-3H-pyrimidin-4-one 
• 2049-80-1 (2-propenyl)propanedioic acid diethyl ester 
• 16019-30-0 6-hydroxy-5-(2-propen-1-yl)-4(1H)-pyrimidinone 

Downstream Products

• 16019-33-3 2-(4,6-dichloropyrimidin-5-yl)acetaldehyde 
• 1001397-14-3 6-chloro-N-[2-fluoro-4-(methylsulfonyl)phenyl]-5-(2-propen-1-yl)-4-pyrimidinamine 
• 1228504-13-9 (5-allyl-6-chloro-pyrimidin-4-yl)-m-tolyl-amine 
• 1001397-65-4 4-bromo-N-[2-(4,6-dichloro-5-pyrimidinyl)ethyl]-2,5-difluoroaniline 
• 1001397-58-5 4-{[6-chloro-5-(2-propen-1-yl)-4-pyrimidinyl]amino}-2,5-difluorobenzonitrile 
• 1309377-57-8 C₁₈H₂₀ClFN₄O₂ 
• 1309377-58-9 C₁₄H₈ClFN₄ 
• 1309386-92-2 C₂₆H₂₈FN₅O₄ 
• 1309377-26-1 C₂₆H₂₈FN₅O₄ 

Relevant academic research and scientific papers

An improved synthesis of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine

[Figure not available: see fulltext.] An improved seven-step synthesis of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine from dimethyl malonate with 31% overall yield is described. The procedure is operationally simple and practical for the synthesis of the 4-chloro-7H-pyrrolo[2,3-d]pyrimidine building block.

ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY

The invention provides a series of conformationally stable and selective kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly inter

Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors

Many biologically active molecules exist as rapidly interconverting atropisomeric mixtures. Whereas one atropisomer inhibits the desired target, the other can lead to off-target effects. Herein, we study atropisomerism as a possibility to improve the sele

TMPZnOPiv?LiCl: A new base for the preparation of air-stable solid zinc pivalates of sensitive aromatics and heteroaromatics

A wide range of aryl and heteroaryl zinc pivalates bearing sensitive functionalities were prepared by selective metalation using TMPZnOPiv?LiCl, a new hindered zinc amide base. The new zinc reagents are easy-to-handle solids, which maintain their activity almost entirely (>95%) after 4 h of air exposure and smoothly undergo Negishi cross-couplings and reactions with various electrophiles such as Cu(I)-catalyzed acylations and allylations.

A ring-closing metathesis approach to heterocycle-fused azepines

Heterocycle-fused azepines, an important class of molecular scaffold, are readily synthesised through the ruthenium-catalysed ring-closing metathesis reaction. Although benzo-fused azepines are well documented, heterocycle-fused examples are poorly developed. Herein, a range of five- and six-membered heterocycle-fused azepines are investigated, allowing access to a series of pharmaceutically interesting products.

CYCLOLIC HYDRAZINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS

Compounds of Formula I are provided, including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: wherein Z is selected from the group consisting of: which are useful as HIV attachment inhibitors.

Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available g protein-coupled receptor 119 agonists

GPR119 is a 7-transmembrane receptor that is expressed in the enteroendocrine cells in the intestine and in the islets of Langerhans in the pancreas. Indolines and 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines were discovered as G protein-coupled receptor 119

PRODUCTION AND USE OF ZINC AMIDES

The application relates to a reagent of the general formula [in-line-formulae]R1R2N—ZnY LiY??(I)[/in-line-formulae] wherein R1, R2 are, independently, selected from H, substituted or unsubstituted aryl or heteroaryl containing one or more heteroatoms, linear, branched or cyclic, substituted or unsubstituted alkyl, alkenyl, alkynyl, or silyl derivatives thereof; and R1 and R2 together can be part of a cyclic or polymeric structure; and wherein at least one of R1 and R2 is other than H; Y is selected from the group consisting of F; Cl; Br; I; CN; SCN; NCO; Halon, wherein n=3 or 4 and Hal is selected from Cl, Br and I; NO3; BF4; PF6; H; a carboxylate of the general formula RXCO2; an alcoholate of the general formula ORX; a thiolate of the general formula SRX; RXP(O)O2; or SCORX; or SCSRX; OnSRx; wherein n=2 or 3; or NOn, wherein n=2 or 3; and a derivative thereof; wherein Rx is a substituted or unsubstituted aryl or heteroaryl containing one or more heteroatoms, linear, branched or cyclic, substituted or unsubstituted alkyl, alkenyl, alkynyl, or derivatives thereof, or H; or as adduct with a solvent; as well as to the preparation and use thereof. 34

FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Fused Bicyclic Pyrimidine Derivatives, compositions comprising a Fused Bicyclic Pyrimidine Derivative, and methods of using the Fused Bicyclic Pyrimidine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G-protein coupled receptor (GPCR) in a patient.

BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS

The present invention relates to Bicyclic Heterocycle Derivatives of Formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metaboli